Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 64

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 64
---
 that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2025 utilized the following inputs:

SCHEDULE OF DERIVATIVE LIABILITY ON CONVERTIBLE NOTES USING BLACK SCHOLES PRICING MODEL

| Schedule of Derivative liability |     |                   |   |
| Risk Free Interest Rate          |     |              4.24 | % |
| Expected Term                    |     | 0.18 – (5.16) Yrs |   |
| Expected Volatility              |     |            184.01 | % |
| Expected Dividends               |     |                 - |   |

Income Taxes

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions
of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated
with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute
of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result
in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results
of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September
30,